EUVIMEDEUVIMED entdecken
Open Access

Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy

Yoshihisa Mimura, Taku Naiki, Yosuke Sugiyama, Yoshihiko Tasaki, Kunihiro Odagiri, Toshiki Etani, Takashi Nagai, Moeko Iida, Yuka Kimura, Nanami Ito, Yuji Hotta, Takahiro Yasui und 1 weitere

Cancer Diagnosis & Prognosis · 01.07.2024 · 4 (4) · 475-481

DOI: 10.21873/cdp.10351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.07.2024. Verfasst von Yoshihisa Mimura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: Cancer cachexia is associated with poor prognosis in patients with metastatic urothelial carcinoma (mUC). The objective of the study was to assess the cachexia index (CXI), which is a new indicator assessing the status of cancer cachexia, as a prognostic indicator for mUC patients treated with gemcitabine plus cisplatin (GC) chemotherapy. Patients and Methods: The study included 55 patients with mUC who underwent GC chemotherapy between 2008 and 2022 as first-line chemotherapy. The CXI at the start of chemotherapy was determined as follows: CXI=(serum albumin × skeletal muscle mass index)/ (neutrophil count/lymphocyte count). Patients were categorized into two groups based on a median CXI value (CXI-high and CXI low). We used Kaplan–Meier curves and multivariate Cox proportional hazards regression models to assess the association between the CXI and overall survival (OS). Results: At the start of GC chemotherapy, significant differences were not found in patients' characteristics. The median OS was significantly shorter in the CXI-low group [10.0 months (95% confidence interval (CI)=5.1-12.8)] than in the CXI-high group [22.3 months (95% CI=13.6-NA), p

Schlagwörter

Stichwörter der Autor:innen

Cancer cachexiachemotherapyurothelial carcinoma

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
  • Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.

Zitieren

APA

Mimura, Y., Naiki, T., Sugiyama, Y., Tasaki, Y., Odagiri, K., Etani, T., Nagai, T., Iida, M., Kimura, Y., Ito, N., Hotta, Y., Yasui, T., & Furukawa-Hibi, Y. (2024). Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy. Cancer Diagnosis & Prognosis, 4(4), 475-481. https://doi.org/10.21873/cdp.10351

Vancouver

Mimura Y, Naiki T, Sugiyama Y, Tasaki Y, Odagiri K, Etani T, et al. Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy. Cancer Diagnosis & Prognosis. 2024;4(4):475-481. doi:10.21873/cdp.10351

BibTeX
@article{Mimura2024,
  author = {Mimura, Yoshihisa and Naiki, Taku and Sugiyama, Yosuke and Tasaki, Yoshihiko and Odagiri, Kunihiro and Etani, Toshiki and Nagai, Takashi and Iida, Moeko and Kimura, Yuka and Ito, Nanami and Hotta, Yuji and Yasui, Takahiro and Furukawa-Hibi, Yoko},
  title = {Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy},
  journal = {Cancer Diagnosis & Prognosis},
  year = {2024},
  volume = {4},
  number = {4},
  pages = {475--481},
  doi = {10.21873/cdp.10351}
}
Kostenlos starten →